US 11,806,330 B2
PACA and cabazitaxel for anti-cancer treatment
Yrr Morch, Trondheim (NO); Einar Sulheim, Trondheim (NO); Kjersti Flatmark, Blommenholm (NO); Karianne Giller Fleten, Oslo (NO); Per Stenstad, Trondheim (NO); Heidi Johnsen, Trondheim (NO); and Ruth Schmid, Tiller (NO)
Assigned to SINTEF TTO AS, Trondheim (NO); and OSLO UNIVERSITETSSYKEHUS HF, Oslo (NO)
Filed by SINTEF TTO AS, Trondheim (NO); and Oslo Universitetssykehus HF, Oslo (NO)
Filed on Mar. 27, 2019, as Appl. No. 16/366,596.
Claims priority of application No. 20180429 (NO), filed on Mar. 27, 2018.
Prior Publication US 2019/0298682 A1, Oct. 3, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/337 (2006.01); A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61P 35/04 (2006.01); A61K 47/60 (2017.01); A61K 9/107 (2006.01); A61K 9/16 (2006.01); B82Y 5/00 (2011.01)
CPC A61K 31/337 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1075 (2013.01); A61K 9/1641 (2013.01); A61K 9/5138 (2013.01); A61K 9/5146 (2013.01); A61K 9/5192 (2013.01); A61K 47/60 (2017.08); A61P 35/04 (2018.01); B82Y 5/00 (2013.01)] 7 Claims
 
1. A method for treatment of cancer in a subject, the method comprising intraperitoneally injecting the subject with a poly (alkyl cyanoacrylate) nanoparticle, the nanoparticle comprising 6 to 20 wt % cabazitaxel based on the total weight of the nanoparticle and having a size of 10 to 500 nanometers, wherein the nanoparticle does not include a targeting moiety, wherein the cabazitaxel is encapsulated by the nanoparticle, and wherein the nanoparticle is administered to the subject in an amount sufficient to treat the cancer in the subject,
wherein the cancer is peritoneal carcinomatosis originating from ovarian cancer, colorectal carcinoma, cervical cancer, breast cancer, colon cancer, or prostate cancer, or is pseudomyxoma peritonei, and
wherein the poly(alkyl cyanoacrylate) comprises a cyanoacrylate having a 2-ethyl butyl (EBCA) alkyl chain.